George Rho
Research analyst, long/short equity, special situations, arbitrage

Forthcoming Clinical Trial Results Could Push Prana Shares Even Higher

The subject of this research report is a tiny development-stage biotechnology concern, which means its common stock is, almost by definition, incredibly volatile. Significantly, too, the dual facts that the company's lead new-drug prospect has only completed Phase 2 clinical testing and could be years from commercial viability inject substantial additional uncertainty and risk. That's not all, the results of the two Phase 2 studies haven't even been released yet. Now that all of the prudent investors have been scared off, we highlight here the reasons why we're recommending the shares of Prana Biotechnology Ltd (NASDAQ: PRAN), even if only as an issue worthy of close monitoring. First, an impressive 40 of 42 patients (95.2%) enrolled in one study...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details